You are here

ASH 2024

Regeneron’s R&D approach scores dual wins against Alexion’s Ultomiris and in lymphoma

Pharma Voice

Thu, 12/12/24 - 11:33 am

ASH 2024: Merck’s new ADC posts positive results in first-line DLBCL

Clinical Trials Arena

Wed, 12/11/24 - 11:21 am

clinical trials

zilovertamab vedotin

ASH: Eli Lilly touts novel BTK trial win for Jaypirca as execs defend survival data blemish

Fierce Pharma

Tue, 12/10/24 - 11:10 am

ASH: With survival win against J&J's Darzalex, GSK bolsters case for return of myeloma ADC Blenrep

Fierce Pharma

Mon, 12/9/24 - 09:10 pm

Multiple Myeloma

ASH 2024: AstraZeneca set to take a BiTE out of follicular lymphoma market

Clinical Trials Arena

Mon, 12/9/24 - 11:12 am

follicular lymphoma

ASH: Merck’s ROR1 drug hits the target in first-line lymphoma

Pharmaphorum

Mon, 12/9/24 - 10:38 am

ASH: AstraZeneca proposes fixed-duration Calquence combos in chronic lymphocytic leukemia

Fierce Pharma

Sun, 12/8/24 - 09:53 pm

chronic lymphocytic leukemia